ClinicalTrials.gg

Program

HU-045

A development code.

Its studies are led by Huons Global.

Furthest: phase 3, since Jan 4, 20243 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huons Global32 open or runningphase 3since Jan 4, 2024Mar 16, 2022May 2027phase 3 · NCT07870694

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2022First study: phase 2 study in Glabellar LinesFirst studyNCT05298449 · 50 enrolled · Korea, Republic of
  2. Jan 4, 2024Phase 3 study in Glabellar LinesNCT06205797 · 312 planned · Korea, Republic of
  3. Oct 6, 2026Phase 3 study in Glabellar LinesNCT07870694 · 390 planned · South Korea

Ahead

  1. May 2027Primary completion: phase 3 study in Glabellar LinesNCT07870694

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07870694Glabellar Lines · South Korea3RecruitingMay 2027390
NCT06205797Glabellar Lines · Korea, Republic of3RecruitingNov 30, 2024312
NCT05298449Glabellar Lines · Korea, Republic of2CompletedNov 7, 202250

How it is read

Names in the registry

  • “HU-045”, 3 entries

Codes read as this program: HU045.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.